Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
about
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).Chrysophanol inhibits proliferation and induces apoptosis through NF-κB/cyclin D1 and NF-κB/Bcl-2 signaling cascade in breast cancer cell lines.Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy
P2860
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Impact of neoadjuvant therapy ...... lts of CALGB 40601 (Alliance).
@en
Impact of neoadjuvant therapy ...... urgical results of CALGB 40601
@nl
type
label
Impact of neoadjuvant therapy ...... lts of CALGB 40601 (Alliance).
@en
Impact of neoadjuvant therapy ...... urgical results of CALGB 40601
@nl
prefLabel
Impact of neoadjuvant therapy ...... lts of CALGB 40601 (Alliance).
@en
Impact of neoadjuvant therapy ...... urgical results of CALGB 40601
@nl
P2093
P2860
P1476
Impact of neoadjuvant therapy ...... lts of CALGB 40601 (Alliance).
@en
P2093
Alliance for Clinical Trials in Oncology
Beth Overmoyer
Clifford Hudis
Constance T Cirrincione
David W Ollila
Donald A Berry
Elisa Port
Eric Winer
George Somlo
Harold J Burstein
P2860
P2888
P304
P356
10.1007/S10549-016-4006-6
P407
P577
2016-10-04T00:00:00Z